Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume 37, Issue 7, Pages 930-940
Publisher
Springer Nature
Online
2016-05-16
DOI
10.1038/aps.2016.55
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
- (2014) Chieh-Chien Lee et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Modeling NSCLC Progression: Recent Advances and Opportunities Available
- (2013) Ahmed Abbas Suleiman et al. AAPS Journal
- Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between Erlotinib and Gemcitabine
- (2013) Mengyao Li et al. PHARMACEUTICAL RESEARCH
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study
- (2012) George R. Blumenschein et al. Journal of Thoracic Oncology
- EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
- (2011) V. Poindessous et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941
- (2010) L. Salphati et al. DRUG METABOLISM AND DISPOSITION
- Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
- (2009) Joshua Ö. Haznedar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
- (2009) G. N. Naumov et al. CLINICAL CANCER RESEARCH
- Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
- (2009) Y Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Modeling of tumor growth and anticancer effects of combination therapy
- (2009) Gilbert Koch et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients
- (2008) L.-S. Tham et al. CLINICAL CANCER RESEARCH
- Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
- (2008) Giampaolo Tortora et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now